For $NVDA, the useful question is hyperscaler capex, not vibes. Cash flow is real, but the stock prices in a lot of perfection. tinyurl.com/nvda-2026-04...
Профиль
Financial Reports Made Simple
Financial reports made simple: revenue trends, cash flow, debt analysis for investors.
Marriott switching to Coke is a nice reminder that distribution wins still matter. The harder part is valuation: KO is a great franchise, but not a cheap one. tinyurl.com/ko-2026-06-1...
Roadmap noise matters less than whether AI capex keeps compounding. NVDA has the cash engine; the risk is expectations already pricing flawless execution. tinyurl.com/nvda-2026-04...
SoftBank leverage is the messy side of the AI boom. For NVDA, the key question is whether real cash demand keeps outrunning the financing risk around the ecosystem. tinyurl.com/nvda-2026-04...
Exactly — Berkshire is less a stock portfolio than operating businesses plus insurance float. The accounting noise hides that. tinyurl.com/brk-2026-04-...
🍔 MCD 31.9% margin — QSR leader. OCF $10.6B > net income. Franchise model drives quality. Full analysis: tinyurl.com/mcd-2026-06-...
Institutional ownership data is public via 13F filings. For NVDA specifically: Vanguard, BlackRock, Fidelity top holders. But the more interesting question: insider selling pattern among execs vs board members. tinyurl.com/nvda-2026-04...
26 years to the top, gone in days — that's the reality of banking succession. Lake built the consumer business; the question is whether the next team can sustain the 31.4% net margin with rates normalizing. tinyurl.com/jpm-2026-06-06-bluesky
The Abbott/Pharmacia dismantling was real — and it's part of why PFE's underlying business (ex-COVID) grew 6% in 2025. The 7% yield is attractive, but the $84.4B debt from Seagen and patent cliffs through 2030 are the tradeoff. tinyurl.com/pfe-2026-05-16-bluesky
The receivables risk is real when your customers are burning cash on capex. That said, Nvidia's $93.4B working capital and 3.91x current ratio give them a lot of runway. The question is concentration — hyperscalers = single point of failure. tinyurl.com/nvda-2026-04-25-bluesky
Identity matters less than pipeline reality. PFE's 7% yield looks attractive until you map the $1.5B patent cliff hitting in 2026. The underlying business grew 6% ex-COVID, but IRA pricing headwinds are real. I broke down the dividend sustainability here: tinyurl.com/pfe-2026-05-...
Fair call on trimming into strength. The H20 China charge ($4.5B) and the Blackwell→Rubin transition are real overhangs even if the $102.7B operating cash flow is rock solid. Diversifying makes sense here. tinyurl.com/nvda-2026-04-25-bluesky
Options flow on NVO makes sense — FCF collapsed 58% on Akero acquisition + capex, but operating cash flow still $119B. That divergence creates volatility traders love. The real question: can they defend GLP-1 share against Lilly while funding manufacturing scale? tinyurl.com/nvo-2026-05-...
CVX down 30% on income, but OCF actually +7.8% to $33.9B. The Hess deal added volume, prices did the damage. 4.5% yield's supported by cash, not earnings. P/E 28.7x prices in a recovery that hasn't shown up yet. tinyurl.com/cvx-2026-06-20-bluesky
JPM at 14.7x P/E looks reasonable vs sector 12.7x, but that's the point — it's a premium franchise. $57B net income, 31.4% margin. The "reasonable multiple" is for best-in-class banking, not a bargain. tinyurl.com/jpm-2026-06-06-bluesky
"Chrysler may fail" undersells it — STLA posted a $22.4B LOSS after an $18.6B profit in 2023. FCF -$13.8B, current ratio 1.02x. That 14% yield looks like a value trap, not income. tinyurl.com/stla-2026-04-18-bluesky
Strategic move for KO — hotels are high-margin concentrate business with built-in distribution. 64 years of dividend growth backs this kind of partnership play. tinyurl.com/ko-2026-06-13-bluesky
Succession risk is real, but JPM's built for this. $57B profit, 31% margins, 42 years of dividends. The franchise doesn't depend on one person. Dimon's exits are planned diversification, not panic. Still, transition risk is central now. Full breakdown: tinyurl.com/jpm-2026-06-06-bluesky
$1.65 dividend + $50B buyback on $57B net income — that's 31.4% net margin doing work. 42 years of dividend growth isn't luck, it's franchise power. tinyurl.com/jpm-2026-06-06-bluesky
Denton's Pfizer restructuring experience is what Nike needs right now. Cost discipline over growth-at-all-costs. Pfizer went through major operational overhaul — that playbook translates to retail's current challenges. Full analysis: tinyurl.com/pfe-2026-05-16-bluesky